Assertio Holdings, Inc. (ASRT)

Assertio Holdings, Inc. stock has trended up significantly in the past six months. A reverse stock split was enacted to maintain its Nasdaq listing. A tender offer for acquiring shares was delayed, following an updated merger deal with Garda Therapeutics. The company reported its fourth-quarter and full-year 2025 results, showing lower revenue and a wider net loss, and initiated fiscal 2026 revenue guidance in the range of $110 million to $125 million.

Information regarding explicit demand seasonality for Assertio Holdings, Inc.'s products is not readily available. The company's focus on expanding products like Rolvedon and Sympazan is noted to benefit from rising demand tied to the increasing prevalence of chronic conditions and an aging population, suggesting a more consistent demand driver.

Assertio Holdings, Inc. is a commercial pharmaceutical company focused on acquiring, licensing, and marketing approved products, primarily targeting neurology, rheumatology, and pain and inflammation, with a growing focus on oncology. Major products include INDOCIN for arthritis, Sympazan for seizures, CAMBIA for migraines, SPRIX for pain management, ROLVEDON for reducing infection risk during chemotherapy, Otrexup as a methotrexate injection, Zipsor for mild to moderate pain relief, and OXAYDO tablets.

Assertio Holdings, Inc. primarily serves patients in the United States. Its commercial operations and revenue are almost entirely derived from the U.S. market, with no disclosed plans for international expansion.

Assertio Holdings, Inc. focuses on marketing differentiated products to address patient needs in oncology, neurology, and pain management. The company has shifted its growth strategy to prioritize its core asset, Rolvedon. While there were no specific negative reputation crisis events, the company has faced challenges related to declining revenue and profitability metrics. Legal fees and a settlement from early 2025 are now behind the company.

Major institutional owners of Assertio Holdings, Inc. include Nantahala Capital Management, LLC, Vanguard Group Inc, Renaissance Technologies LLC, Edgewood Management LLC, BlackRock, Inc., Geode Capital Management, LLC, Huntleigh Advisors, Inc., CM Management, LLC, and Citadel Advisors LLC. Other notable institutional holders include State Street and Morgan Stanley. Insider ownership in the company is small.